TABLE 1.
List of evaluated psychiatric drugs.
| Psychiatric drug | References | Study design | N | SIGN | Jadad Scale | |
| Antidepressants | Paroxetine | Kavanagh et al. (21) | Randomized, double-blind, placebo controlled, and crossover design | 15 | + | 3 |
| Strachan et al. (22) | Randomized, double-blind, placebo controlled, and crossover design | 8 | ++ | 4 | ||
| Strüder et al. (23) | Randomized, double-blind, placebo controlled, and crossover design | 10 | ++ | 3 | ||
| Teixeira-Coelho et al. (24) | Randomized, double-blind, placebo controlled, and crossover design | 16 | ++ | 4 | ||
| Thorstensen et al. (25) | Randomized, double-blind, placebo controlled, and crossover design | 15 | + | 3 | ||
| Wilson et al. (26) | Randomized, double-blind, placebo controlled, and crossover design | 7 | ++ | 5 | ||
| Fluoxetine | Meeusen et al. (27) | Randomized, double-blind, placebo controlled, and crossover design | 8 | ++ | 4 | |
| Parise et al. (19) | Randomized, double-blind, placebo controlled, and crossover design | 11+12 | ++ | 5 | ||
| Sertraline | Bilici et al. (28) | Case control study | 38 | + | / | |
| Fluvoxamine | ||||||
| Citalopram | ||||||
| Bupropion | Cordery et al. (29) | Randomized, double-blind, placebo controlled, and crossover design | 9 | ++ | 4 | |
| Onus et al. (30) | Randomized single-blind design | 8 | + | 3 | ||
| Piacentini et al. (31) | Randomized, double-blind, placebo controlled, and crossover design | 8 | ++ | 4 | ||
| Roelands et al. (20) | Randomized, double-blind, placebo controlled, and crossover design | 8 | ++ | 4 | ||
| Roelands et al. (32) | Randomized, double-blind, placebo controlled, and crossover design | 10 | ++ | 4 | ||
| Watson et al. (6) | Randomized, double-blind, placebo controlled, and crossover design | 9 | ++ | 4 | ||
| Reboxetine | Goekint et al. (33) | Randomized, double-blind, placebo controlled, and crossover design | 11 | ++ | 4 | |
| Klass et al. (34) | Randomized, double-blind, placebo controlled, and crossover design | 10 | ++ | 4 | ||
| Klass et al. (35) | Randomized, double-blind, placebo controlled, and crossover design | 9 | + | 4 | ||
| Piacentini et al. (36) | Randomized, double-blind, placebo controlled, and crossover design | 7 | ++ | 4 | ||
| Roelands et al. (37) | Randomized, double-blind, placebo controlled, and crossover design | 9 | ++ | 4 | ||
| Ritanserin | Meeusen et al. (38) | Randomized, double-blind, placebo controlled, and crossover design | 7 | ++ | 4 | |
| Antipsychotics | Oxypertine | Adamson and Finlay (17) | Randomized, double-blind, and crossover design | 5 | − | 3 |
| Clozapine | Kim et al. (39) | Cross-sectional study | 30 + 15 | + | / | |
| Olanzapine | Perez-Cruzado et al. (40) | Cross-sectional study | 62 | + | / | |
| Risperidone | ||||||
| Sedatives | Benzodiazepine | Charles et al. (18) | Randomized, double-blind, placebo controlled, and crossover design | 8 + 27 | + | 4 |
| Collomp et al. (41) | Randomized, double-blind, placebo controlled, and crossover design | 7 | ++ | 4 | ||
| Collomp et al. (42) | Randomized, double-blind, placebo controlled, and crossover design | 7 | ++ | 4 | ||
| Ergen et al. (43) | Randomized, double-blind, placebo controlled, and crossover design | 24 | ++ | 4 | ||
| Grobler et al. (44) | Randomized, double-blind, placebo controlled, and crossover design | 12 | ++ | 4 | ||
| Z-drugs | Grobler et al. (44) | Randomized, double-blind, placebo controlled, and crossover design | 12 | ++ | 4 | |
| Suda et al. (45) | Randomized, double-blind, placebo controlled, and crossover design | 12 | ++ | 3 | ||
| Ito et al. (8) | Randomized, double-blind, placebo controlled, and crossover design | 8 | ++ | 3 | ||
| Ito et al. (46) | Randomized, double-blind, placebo controlled, and crossover design | 21 | ++ | 3 | ||
| Tafti et al. (9) | Randomized, double-blind, placebo controlled, and crossover design | 8 | ++ | 2 | ||
| Stimulants | Methylphenidate | King et al. (47) | Randomized, double-blind, placebo controlled, and crossover design | 15 | − | 3 |
| Klass et al. (34) | Randomized, double-blind, placebo controlled, and crossover design | 10 | ++ | 4 | ||
| Roelands et al. (48) | Randomized, double-blind, placebo controlled, and crossover design | 8 | ++ | 4 | ||
| Others | Westover et al. (49) | Cross-sectional study | 245 | + | / | |
N, total sample size; SIGN, ++, high quality; +, acceptable, −, low quality; Jadad Scale, 0–5 (with 5 as the maximum; /, not applicable).